Grayline Research Center | Wichita Falls, TX

Research site

(Unclaimed)

Location

3300 Seymour Highway, Wichita Falls, Texas, United States of America

Site insights

Top conditions

Top treatments

Pimavanserin

ATH-1017

Simufilam

ABBV-932

Troriluzole

BI 1569912

BHV-7000

SP-624

BI 1358894

Seltorexant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 34 total trials

Locations recently updated

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn...

Enrolling

Early Alzheimers Disease

Drug: buntanetap/posiphen

Drug: Placebo

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA2)

X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Enrolling

Major Depressive Disorder

Drug: Placebo

Drug: Azetukalner

A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020...

Enrolling

Alzheimer Disease

Drug: Placebo

Drug: ONO-2020

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Enrolling

Major Depressive Disorder

Drug: SP-624

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)

Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Al...

Enrolling

Alzheimer Disease

Dementia

Drug: MK-1167

Drug: Placebo

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling

Obsessive-Compulsive Disorder

Drug: Placebo

Drug: Troriluzole

Locations recently updated

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Enrolling

Major Depressive Disorder

Drug: BHV-7000

Drug: Placebo

ENCALM: a Study of ENX-102 As a Monotherapy Treatment in Patients with Generalized Anxiety Disorder

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Enrolling

Generalized Anxiety Disorder

Drug: Placebo

Drug: ENX-102

GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The mai...

Enrolling

Major Depressive Disorder

Drug: Zelquistinel

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only

Obsessive Compulsive Disorder

Drug: Troriluzole (BHV-4157)

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Invitation-only

Major Depressive Disorder

Drug: BHV-7000

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with plac...

Enrolling

Depressive Disorder, Major

Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

Drug: Placebo

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO)

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how saf...

Enrolling

Bipolar II Disorder

Bipolar I Disorder

Drug: Placebo for ABBV-932

Drug: ABBV-932

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately t...

Enrolling

Generalized Anxiety Disorder (GAD)

Drug: Antidepressant Therapy (ADT)

Drug: ABBV-932